Sino Biopharm's TQB2102 shows promising HER2 ADC data
Sino Biopharmaceutical Limited (HKEX: 1177) has announced encouraging preliminary data from its Phase I clinical trial of TQB2102, a bispecific anti-HER2 ADC. The study, involving 181 patients with advanced solid tumors, demonstrated notable efficacy, with objective remission rates (ORR) of 51.3% in HER2-positive breast cancer and 51.5% in HER2 low-expression breast cancer for the dose group of 6mg/kg and above. Additionally, HER2 high-expression colorectal cancer showed a 34.8% ORR, while HER2-positive gastric cancer or gastroesophageal junction cancer showed a 70% ORR. Notably, 70% of HER2-positive breast cancer patients with brain metastasis also showed an ORR, with one case of intracranial lesion in complete remission. 31% of breast cancer subjects remained effective after T-DM1/DS-8201 resistance. In terms of safety, Grade ≥3 adverse events (AEs) were mainly neutropenia (21.7%). There was only one case (0.55%) of grade 2 interstitial lung disease (ILD), which is lower than that of the comparable drug DS-8201 (incidence >10%). Phase III clinical trials are currently underway.
This report was generated by FilingReader's AI system from regulatory filings and company disclosures. To request a correction, contact editorial@filingreader.com
News Alerts
Get instant email alerts when Sino Biopharmaceutical publishes news
Free account required • Unsubscribe anytime